E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The medical condition to be evaluated is the analgesic response of people with chronic low back pain who are going to be treated with opioids, guided by omics sciences (pharmacogenetics, epigenetics and metabolomics). |
La condición médica a evaluar es la respuesta analgésica de las personas con dolor crónico causado por lumbalgia que van a ser tratadas con opioides, cuyo tratamiento será guiado por las ciencias ómicas (farmacogenética, epigenética y metabolómica). |
|
E.1.1.1 | Medical condition in easily understood language |
The medical condition to be evaluated is the analgesic response of people with chronic low back pain who are going to be treated with opioids, guided by genetics information. |
La condición médica a evaluar es la respuesta analgésica de las personas con dolor crónico causado por lumbalgia que van a recibir tratamiento con opioides, guiado según su información genética. |
|
E.1.1.2 | Therapeutic area | Health Care [N] - Health Care Quality, Access, and Evaluation [N05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to understand through pharmacogenetic markers and epigenetic changes, the different response to opioid analgesics appreciated in women. |
El objetivo principal es comprender a través de marcadores farmacogenéticos y cambios epigenéticos, la diferente respuesta a los analgésicos opioides apreciada en las mujeres. |
|
E.2.2 | Secondary objectives of the trial |
1. Identify the metabolic profile according to the activity of the CYP2D6 enzyme. 2. Analyze the epigenetic expression of the OPRM1 and COMT genes, based on sex, their genetic variants and analgesic response. 3. Analyze pharmacokinetics (AUC, Cmax) based on sex and analgesic response, determining the plasma concentrations of analgesics (tramadol, morphine or fentanyl) and their active metabolites. 4. Analyze the influence of the hormonal profile and the moment of the menstrual cycle, and its relationship with the analgesic response. 5. Study the influence of gender roles (sociocultural) on the analgesic response. |
1. Identificar el perfil metabólico según la actividad de la enzima CYP2D6. 2. Analizar la expresión epigenética de los genes OPRM1 y COMT, en función del sexo, sus variantes genéticas y respuesta analgésica. 3. Analizar la farmacocinética (AUC, Cmax) en función del sexo y la respuesta analgésica, determinando las concentraciones plasmáticas de analgésicos (tramadol, morfina o fentanilo) y sus metabolitos activos. 4. Analizar la influencia del perfil hormonal y el momento del ciclo menstrual, y su relación con la respuesta analgésica. 5. Estudiar la influencia de los roles de género (socioculturales) en la respuesta analgésica. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1- Patients over 18 years of age. 2- Low back pain for more than 6 months, as a model of non-cancer chronic pain. 3- Patients naïve to opioids and who require analgesic treatment with opioids (tramadol, morphine or fentanyl). |
1- Pacientes mayores de 18 años. 2- Lumbalgia durante más de 6 meses, como modelo de dolor crónico no oncológico. 3- Pacientes naïve a opioides y que requieran tratamiento analgésico con opioides (tramadol, morfina o fentanilo). |
|
E.4 | Principal exclusion criteria |
1- Subjects with some type of cancer or metastatic pain. 2- Subjects with use of drugs or products metabolized by CYP2D6. 3- Presence or history of allergy to analgesics or pain treatment aids. 4- Pregnant women 5- Presence or history of abuse of prohibited substances. 6- Patients with a history of psychiatric disability that the researcher considers clinically significant, and that prevents the patient from granting their consent or interferes with the proper development of the study. 7- Participants in any other trial during the study period or 30 previous days. 8- Patients who deny their informed consent in writing. |
1- Sujetos con algún tipo de cáncer o dolor metastásico. 2- Sujetos con uso de fármacos o productos metabolizados por CYP2D6. 3- Presencia o antecedentes de alergia a analgésicos o auxiliares para el tratamiento del dolor. 4- Mujeres embarazadas 5- Presencia o historial de abuso de sustancias prohibidas. 6- Pacientes con antecedente de discapacidad psiquiátrica que el investigador considere clínicamente significativo, y que impida al paciente otorgar su consentimiento o interfiera con el correcto desarrollo del estudio. 7- Participantes en cualquier otro ensayo durante el período de estudio o 30 días previos. 8- Pacientes que denieguen su consentimiento informado por escrito. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
In the first part of the project, we will study the relationship between the analgesic response of patients with chronic pain, and their genetic / epigenetic information for the COMT, OPRM1 and CYP2D6 genes. It is expected to find a lower analgesic response, in women, extreme CYP2D6 phenotypes (slow or ultrafast), which present a higher % of methylation in the OPRM1 (position +117) and COMT genes. |
En la primera parte del proyecto estudiaremos la relación entre la respuesta analgésica de pacientes con dolor crónico y su información genética / epigenética para los genes COMT, OPRM1 y CYP2D6. Se espera encontrar una menor respuesta analgésica en mujeres, fenotipos extremos de CYP2D6 (lento o ultrarrápido), que presentan un mayor % de metilación en los genes OPRM1 (posición +117) y COMT. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
In the second part of the project, patients will be grouped in a group guided by sex and omics and a control group. The group guided by sex and omics will be treated taking into account their genetic/epigenetic information. The control group will follow the usual treatment. We expect to get better analgesic response in the group guided by sex and genetic/epigenetic information. |
En la segunda parte del proyecto, los pacientes se agruparán en un grupo guiado por sexo y ómicas y un grupo de control. El grupo guiado por el sexo y las ómicas será tratado teniendo en cuenta su información genética / epigenética. El grupo de control seguirá el tratamiento habitual. Esperamos obtener una mejor respuesta analgésica en el grupo guiado por el sexo y la información genética / epigenética. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At the end of the study, 4 years. |
Al final del estudio, 4 años. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Tipo de tratamiento “guiado” por sexo y ómicas (caso) vs. otro sin información (control) |
Type of treatment “guided” by sex and omics (case) vs. another without information(control) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |